29 June 2026
In this short video, MPP Executive Director Charles Gore reflects on the invaluable contributions of CAP members over the past three years and how community voices continue to shape MPP’s work to improve access to health technologies worldwide. As the first three-year term of the Medicines Patent Pool’s Community Advisory Panel (CAP) comes to a close for most members, MPP is launching a call for applications to bring new voices to the panel, particularly from underrepresented regions and disease areas.
More on MPP’s Community Advisory Panel
Access the Call for Application
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of innovative medicines and other health technologies for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed health products and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 23 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, one antiviral treatment for influenza, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada and Coeffient Giving. MPP’s activities in technology transfer are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, the Government of Flanders and SDC.